PureTech Health PLC (PRTC) - Net Assets
Based on the latest financial reports, PureTech Health PLC (PRTC) has net assets worth $369.02 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($553.24 Million) and total liabilities ($184.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PRTC cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $369.02 Million |
| % of Total Assets | 66.7% |
| Annual Growth Rate | N/A |
| 5-Year Change | -37.58% |
| 10-Year Change | 148.66% |
| Growth Volatility | 100.51 |
PureTech Health PLC - Net Assets Trend (2012–2024)
This chart illustrates how PureTech Health PLC's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of PureTech Health PLC for the complete picture of this company's asset base.
Annual Net Assets for PureTech Health PLC (2012–2024)
The table below shows the annual net assets of PureTech Health PLC from 2012 to 2024. For live valuation and market cap data, see PureTech Health PLC (PRTC) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $407.93 Million | -10.98% |
| 2023-12-31 | $458.23 Million | -16.32% |
| 2022-12-31 | $547.59 Million | -6.26% |
| 2021-12-31 | $584.15 Million | -10.62% |
| 2020-12-31 | $653.54 Million | +0.48% |
| 2019-12-31 | $650.40 Million | +289.53% |
| 2018-12-31 | $166.97 Million | +160.91% |
| 2017-12-31 | $64.00 Million | -30.75% |
| 2016-12-31 | $92.41 Million | -43.67% |
| 2015-12-31 | $164.05 Million | +22.71% |
| 2014-12-31 | $133.69 Million | +1765.47% |
| 2013-12-31 | $-8.03 Million | -139.33% |
| 2012-12-31 | $-3.35 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to PureTech Health PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6338300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $32.49 Million | 7.83% |
| Common Stock | $4.86 Million | 1.17% |
| Other Comprehensive Income | $133.96 Million | 32.30% |
| Other Components | $243.40 Million | 58.69% |
| Total Equity | $414.71 Million | 100.00% |
PureTech Health PLC Competitors by Market Cap
The table below lists competitors of PureTech Health PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yibin Paper Industry Co Ltd
SHG:600793
|
$422.21 Million |
|
Logan Energy Corp
V:LGN
|
$422.28 Million |
|
Lontrue Co Ltd
SHE:300175
|
$422.31 Million |
|
AS Tallink Grupp
HE:TALLINK
|
$422.35 Million |
|
Sofwave Medical Ltd
TA:SOFW
|
$421.94 Million |
|
Paysafe Ltd
NYSE:PSFE
|
$421.78 Million |
|
LH Hotel Leasehold Real Estate Investment Trust
BK:LHHOTEL
|
$421.75 Million |
|
Shanghai Menon Animal Nutrition Technology Co. Ltd.
SHE:301156
|
$421.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PureTech Health PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 464,066,000 to 414,707,000, a change of -49,359,000 (-10.6%).
- Net income of 53,510,000 contributed positively to equity growth.
- Share repurchases of 107,559,000 reduced equity.
- New share issuances of 895,000 increased equity.
- Other comprehensive income increased equity by 4,814,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $53.51 Million | +12.9% |
| Share Repurchases | $107.56 Million | -25.94% |
| Share Issuances | $895.00K | +0.22% |
| Other Comprehensive Income | $4.81 Million | +1.16% |
| Other Changes | $-1.02 Million | -0.25% |
| Total Change | $- | -10.64% |
Book Value vs Market Value Analysis
This analysis compares PureTech Health PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.18x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 37.16x to 1.18x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.49 | $18.14 | x |
| 2013-12-31 | $-0.14 | $18.14 | x |
| 2014-12-31 | $21.71 | $18.14 | x |
| 2015-12-31 | $12.20 | $18.14 | x |
| 2016-12-31 | $7.74 | $18.14 | x |
| 2017-12-31 | $8.97 | $18.14 | x |
| 2018-12-31 | $10.06 | $18.14 | x |
| 2019-12-31 | $22.90 | $18.14 | x |
| 2020-12-31 | $22.87 | $18.14 | x |
| 2021-12-31 | $20.71 | $18.14 | x |
| 2022-12-31 | $19.04 | $18.14 | x |
| 2023-12-31 | $16.80 | $18.14 | x |
| 2024-12-31 | $15.38 | $18.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PureTech Health PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.90%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1108.33%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.45x
- Recent ROE (12.90%) is above the historical average (-29.51%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -357.27% | -139.36% | 0.41x | 6.20x | $-11.36 Million |
| 2013 | 0.00% | -61.31% | 0.42x | 0.00x | $-4.21 Million |
| 2014 | -23.26% | -2069.73% | 0.01x | 1.27x | $-59.54 Million |
| 2015 | -17.42% | -335.55% | 0.04x | 1.45x | $-62.01 Million |
| 2016 | -27.46% | -1101.15% | 0.01x | 1.68x | $-66.56 Million |
| 2017 | 14.40% | 4749.08% | 0.00x | 1.59x | $9.44 Million |
| 2018 | -15.84% | -266.65% | 0.04x | 1.60x | $-71.20 Million |
| 2019 | 63.04% | 4847.42% | 0.01x | 1.41x | $354.34 Million |
| 2020 | 0.89% | 71.75% | 0.01x | 1.48x | $-60.99 Million |
| 2021 | -10.20% | -606.85% | 0.01x | 1.59x | $-119.91 Million |
| 2022 | -9.29% | -2409.33% | 0.00x | 1.30x | $-104.58 Million |
| 2023 | -14.16% | -1972.88% | 0.00x | 1.50x | $-112.10 Million |
| 2024 | 12.90% | 1108.33% | 0.01x | 1.45x | $12.04 Million |
Industry Comparison
This section compares PureTech Health PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PureTech Health PLC (PRTC) | $369.02 Million | -357.27% | 0.50x | $421.98 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About PureTech Health PLC
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The co… Read more